Investor Relations

Corporate Profile

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm was founded by Dr. Sharon Shacham in December 2008 and is headquartered in Newton, Massachusetts.

 

Corporate presentation

Corporate Presentation

Stock Quote (NASDAQ: KPTI)

Copyright West LLC. Minimum 15 minutes delayed.